



G Medical Innovations Holdings Ltd  
ARBN 617 204 743

**ASX Announcement**

1 May 2020

## **Completed Oversubscribed Capital Raising**

- **A\$6 million to be raised through the issue of 85,528,236 shares to sophisticated and institutional investors**
- **Funds to be deployed to terminate convertible notes allowing balance sheet flexibility**
- **Placement well supported by a range of new professional investors and institutions**
- **Multiple near term value catalysts pending – GMV now has a strong foundation set for near term growth**

Mobile and e-Health company **G Medical Innovations (ASX: GMV)** ("**G Medical**" or the "**Company**") is pleased to advise that it has received firm commitments from professional, sophisticated and institutional investors to raise A\$6 million (before costs) through the issue of 85,528,236 fully paid ordinary shares in the Company ("**Shares**") ("**Placement**").

It is anticipated that completion of the Placement (which includes issue of Shares under the Placement) will occur on Friday, 8 May 2020. The Shares under the Placement are being issued at the average issue price of A\$0.07 per Share and are being issued pursuant to the shareholder approval obtained by the Company on 19 March 2020 and under the Company's existing Listing Rule 7.1 capacity. Refer to the Appendix 3B which will follow this announcement for further details.

The Company will also issue up to 6 million unlisted options to qualifying brokers and Australian Financial Services License holders who assisted in raising Placement funds, subject to receiving shareholder approval at the next general meeting of shareholders the Company ("**Broker Options**"). Each Broker Option will be exercisable at A\$0.25 and expire 18 months from the date of issue.

The funds raised from the Placement will be used to repay funds to MEF, I.L.P. ("**Magna**") (refer ASX announcements dated 11 February 2020 and 7 April 2020), a portion of loan funds owing to Dr Yacov Geva (Managing Director), for working capital purposes and for the costs of the Placement.

The Company has entered into further arrangements with Magna, pursuant to which the Company will:

- issue 7,142,857 Shares to Magna (at a deemed issue price of A\$0.07) ("**Settlement Shares**"); and
- pay Magna the sum of US\$3,180,501.43 (less the USD equivalent of A\$500,000 based on the USD/AUD exchange rate on 7 May 2020 – having regard to the issue of the Settlement Shares) from the funds raised under the Placement,

in full and final settlement of its outstanding debt to Magna.

The Company will issue the Settlement Shares to Magna on the same day which Shares are issued pursuant to the Placement, being Friday, 8 May 2020, under the Company's existing Listing Rule 7.1 capacity. Refer to the Appendix 3B following this announcement for further details on the Shares to be issued to Magna.

G Medical is confident that the recapitalisation of its debt with Magna will provide the necessary balance sheet flexibility for near term growth. The Company has achieved a number of crucial milestones in the recent months that have created a strong foundation for growth and looks to continue this momentum across the remainder of CY 2020 and beyond.

**CEO and Executive Director Dr Yacov Geva said:** “We are pleased to have received such strong support from professional investors and institutions and welcome a number of new parties to the register.

“The funds raised from this placement allow G Medical to cancel all outstanding convertible notes and will leave the Company well positioned as it enters into its next phase of growth.

“Our medical devices and telehealth solutions are gaining considerable traction in key markets, including the USA, Australia, China, and Europe. These territories remain the key focus for G Medical and we will continue to work with in-country partners to further establish partnerships and pursue additional opportunities that unlock value for our shareholders.”

**Ends**

*Authorised for release by Yacov Geva, Managing Director.*

**Released through:** Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

#### **About G Medical Innovations**

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit [www.gmedinnovations.com](http://www.gmedinnovations.com)

#### **About G Medical products:**

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.